Runx Transcription Factors in T Cells—What Is Beyond Thymic Development?
Runx proteins (also known as Runt-domain transcription factors) have been studied for a long time as key regulators of cellular differentiation. RUNX2 has been described as essential for osteogenesis, whereas RUNX1 and RUNX3 are known to control blood cell development during different stages of cell...
Saved in:
Published in | Frontiers in immunology Vol. 12; p. 701924 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
06.08.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 1664-3224 1664-3224 |
DOI | 10.3389/fimmu.2021.701924 |
Cover
Summary: | Runx proteins (also known as Runt-domain transcription factors) have been studied for a long time as key regulators of cellular differentiation. RUNX2 has been described as essential for osteogenesis, whereas RUNX1 and RUNX3 are known to control blood cell development during different stages of cell lineage specification. However, recent studies show evidence of complex relationships between RUNX proteins, chromatin-modifying machinery, the cytoskeleton and different transcription factors in various non-embryonic contexts, including mature T cell homeostasis, inflammation and cancer. In this review, we discuss the diversity of Runx functions in mature T helper cells, such as production of cytokines and chemokines by different CD4 T cell populations; apoptosis; and immunologic memory acquisition. We then briefly cover recent findings about the contribution of
RUNX1, RUNX2
and
RUNX3
to various immunologic diseases. Finally, we discuss areas that require further study to better understand the role that Runx proteins play in inflammation and immunity. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Edited by: Ichiro Taniuchi, RIKEN Center for Integrative Medical Sciences (IMS), Japan This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology Reviewed by: Remy Bosselut, National Cancer Institute (NCI), United States; Hiroyuki Hosokawa, Tokai University, Japan |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2021.701924 |